The treatment of multiple sclerosis in Latin America: Current practice and optimal standards. The findings of a survey among neurologists at an interactive workshop;Tratamiento de la esclerosis múltiple en Latinoamérica: Práctica actual y estándares óptimos. Resultados de una encuesta a neurólogos durante un taller interactivo

Revista de Neurologia

Volumn 42, Issue 7, 2006, Pages 399-407

  Carrá, Adriana ^a   Rivera Olmos, V ^b   Arcega, R ^c   Gabbai, A ^d   Haussen, S R ^e   Luetic, G ^f   San Pedro, E ^g   Tenembaum, S ^h  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f Instituto de Oncologia de Rosário   (Argentina)

^g Hospital Municipal de San Isidro   (Argentina)

^h HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Diagnosis; Monitoring; Multiple sclerosis; Nuclear magnetic resonance; Treatment

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL PRACTICE; DEMYELINATING DISEASE; HUMAN; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; SOUTH AND CENTRAL AMERICA; STRUCTURED QUESTIONNAIRE; TREATMENT FAILURE; CONSENSUS DEVELOPMENT; DECISION MAKING; EVALUATION; MANPOWER; PATHOLOGY; QUESTIONNAIRE; STANDARD;

CONSENSUS DEVELOPMENT CONFERENCES; DECISION MAKING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LATIN AMERICA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROLOGY; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; TREATMENT FAILURE;

EID: 33750143043     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4207.2005128     Document Type: Article

References (23)

1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
2. Milo R, Panitch H. Glatiramer acetate on interferon-β for multiple sclerosis? A guide to drug choice. CNS Drugs 1999; 11: 289-306.
3. Filippi M, Horsfield MA, Ader HJ, Barkhof F, Bruzzi P, Evans A, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998; 43: 499-506.
4. Prieto JM, Lema M. Interferón β en la esclerosis múltiple. Rev Neurol 2003; 36: 980-90.
5. García Merino JA, Blasco-Quitez MR, Ortiz-Benítez P, Puerta C. Terapia combinada en la esclerosis múltiple. Rev Neurol 2003; 36: 545-9.
6. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78.
7. Izquierdo G. Tratamiento preventivo en la esclerosis múltiple. Normas para el tratamiento con inmunomoduladores Rev Neurol 2002; 35: 1094-9.
8. Lana-Peixoto MA, Callegaro D, Moreira MA, Campos GB, Marchiori PE, Gabbai AA, et al. The BCTRIMS expanded consensus on treatment of multiple sclerosis III. Evidence and recommendation-based guidelines. Arq Neuropsiquiatr 2002; 60: 881-6.
9. Marshall L. New guidelines offer hope for UK patients with MS. Lancet Neurol 2004; 3: 325.
10. Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-68.
11. Comi G, Montalbán X, Birnbaum G, Carrá A, Callegaro D, Chofflon M, et al. Along the winding road: decision making process in the treatment of multiple sclerosis. Outcome of an interactive workshop session. Drugs Focus; 2004. p. 33-44.
12. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
13. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
14. Ford C, Johnson K, Brooks B, Goodman A, Kachuck N, Lisak R, et al. Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over ten years. Mult Scler 2003; 9 (Suppl 1): S120.
15. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, et al. One-third of patients treated with IFNs experienced when compared to baseline a higher or identical annual relapse rate while on IFNβ treatment. Neurology 2003; 61: 184-9.
16. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
17. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001; 7: 349-53.
18. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
19. Hommes OR, Weiner HL. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis. Mult Scler 2002; 8: 139-41.
20. Jacob A, McCoy K, Boggild M. Inducing and maintaining remission in aggressive RRMS: experience of sequential treatment with mitoxantrone and glatiramer acetate. Mult Scler 2003; 9 (Suppl 1): S18.
21. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, et al, Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-66.
22. Carrá A, Onaha P, Sinay V, Álvarez F, Luetic G, Bettinelli R, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003; 10: 671-6.
23. Haas J, Firzlaff M. 24-month comparison of immunomodulatory treatments -a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005; 12: 425-31.